Global Expansion: Biofabri and Bharat Biotech's Tuberculosis Vaccine Initiative

Biofabri and Bharat Biotech have entered a strategic technology transfer agreement to enhance the global distribution of MTBVAC, a promising tuberculosis vaccine candidate.

This partnership builds on a prior licensing agreement and aims to facilitate local manufacturing in over 70 countries across Africa and Southeast Asia.

By enabling production closer to affected regions, the initiative seeks to improve vaccine accessibility and affordability in areas with high tuberculosis prevalence.

MTBVAC is currently undergoing a Phase 3 clinical trial in India, underscoring ongoing efforts to validate its efficacy and safety.

Tuberculosis remains a major global health challenge, particularly in low- and middle-income countries, where vaccine coverage and treatment options are limited.

The collaboration between Biofabri, a European biopharmaceutical company, and Bharat Biotech, an Indian vaccine manufacturer, exemplifies international cooperation to address infectious diseases through technology sharing.

If successful, this approach could accelerate the availability of MTBVAC and contribute to reducing tuberculosis incidence worldwide.

The agreement also highlights the importance of building regional manufacturing capacity to respond effectively to public health needs.

Overall, this initiative represents a significant step toward expanding access to innovative tuberculosis vaccines in vulnerable populations.